Washington, D.C. – A major shift in Alzheimer’s treatment options is underway after federal regulators approved a new use for a drug targeting one of the disease’s most challenging symptoms.
According to the U.S. Food and Drug Administration, Auvelity has been approved to treat agitation associated with dementia due to Alzheimer’s disease in adults, marking the first non-antipsychotic medication authorized for this condition.
Agitation is a common and often severe symptom in Alzheimer’s patients, involving behaviors such as aggression, restlessness, and emotional distress. It can significantly impact both patients and caregivers, often complicating care and reducing quality of life.
Health officials say the approval represents a meaningful step forward. The drug was previously approved in 2022 to treat major depressive disorder, but this expanded use introduces a new option for families and clinicians managing advanced Alzheimer’s symptoms.
Clinical trials played a key role in the decision. In one study, patients taking Auvelity showed significant improvement in agitation scores compared to those receiving a placebo over five weeks. A second study found that patients who continued taking the drug experienced a longer delay before symptoms returned, compared to those who stopped treatment.
Experts say this dual evidence—reducing symptoms and preventing relapse—helped support the approval, which was granted under both breakthrough therapy and priority review designations.
However, the drug is not without risks. Common side effects include dizziness, nausea, headache, and drowsiness. The medication also carries a boxed warning about an increased risk of suicidal thoughts in younger populations taking antidepressants. Doctors are advised to monitor patients closely, particularly during early treatment stages.
Additional risks include seizures, elevated blood pressure, and potential mood changes, especially in patients with a history of bipolar disorder. Health providers are urged to review medical history and current medications before prescribing.
The approval gives doctors a new tool in addressing agitation, a symptom that has long lacked targeted treatments outside of antipsychotic drugs, which can carry significant side effects.
For families facing Alzheimer’s disease, the decision may offer a new layer of hope—particularly as the condition progresses and symptoms become more difficult to manage.
